PCI Biotech announced the appointment of Dr. Amir Snapir, MD, PhD as Chief Medical Officer (CMO). Dr. Snapir will also serve as a member of PCI Biotech's executive management team. He will lead the execution of all clinical development programmes, and be a key contributor to the identification and implementation of new opportunities and pipeline expansions. Dr. Snapir brings extensive experience in global clinical development of novel therapeutics, from early clinical translation to marketing authorisation, combined with extensive international regulatory experience. Dr. Snapir also brings years of experience in business collaborations, alliances and product co- developments. Since 2007 Dr. Snapir has held various positions at Orion Pharma, Espoo, Finland, spanning from leader of clinical pharmacogenomics to clinical development leader in Oncology. In his most recent role, Dr. Snapir held the position as Director, Rare Disease Development. Dr. Snapir will commence as CMO no later than 1 May 2020.